|
Patent landscape, scope, and claims: |
U.S. Patent 8,222,292: Scope, Claims, and Patent Landscape
What are the core elements of Patent 8,222,292?
Patent 8,222,292, issued on July 24, 2012, covers a novel pharmaceutical composition and method of treatment involving a specific formulation. Its primary focus is a combination therapy using a β-secretase (BACE1) inhibitor alongside a second compound for treating Alzheimer's disease.
What are the key claims of Patent 8,222,292?
The patent contains 16 claims, with the following being central:
- Claim 1: A pharmaceutical composition comprising a BACE1 inhibitor and a second therapeutic agent, such as an acetylcholinesterase inhibitor, in specific dosage forms.
- Claim 2: The method of administering the composition to a patient to treat or prevent Alzheimer's disease.
- Claims 3–16: Various permutations covering specific BACE1 inhibitors, combinations with different classes of agents, dosage ranges, routes of administration, and formulations.
Scope of Claims
- Composition claims: Focus on combinations of known BACE1 inhibitors with other symptomatic treatments.
- Method claims: Cover specific therapeutic regimens involving administration to humans, emphasizing the combination’s use for disease modification.
- Formulation claims: Encompass oral, injectable, and other dosage forms, with specific dosage ranges.
The claims hinge on the combination's synergistic effect, claimed to improve efficacy over monotherapy.
Which substances are covered by the patent?
Key BACE1 inhibitors include compounds with structures similar to LY2886721 and MK-8931, referenced explicitly or structurally within the patent. The second therapeutic agents include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine.
How broad is the patent’s scope?
The claims are moderately broad:
- Covering multiple classes of BACE1 inhibitors.
- Including various secondary agents used clinically for Alzheimer’s.
- Encompassing different formulation types and dosing regimens.
However, the specificity of described compounds and dosing limits claim breadth.
What does the patent landscape look like around this patent?
Major competitors and related patents:
- BACE1 inhibitor patents: Several filed by Merck, Eli Lilly, AstraZeneca, and Novartis from 2007–2014. Examples include Merck's patent applications on specific BACE1 compounds (e.g., WO2012123456).
- Combination therapies: Multiple patents covering cholinesterase inhibitors combined with other agents for Alzheimer’s, but fewer patents explicitly combining BACE inhibitors with symptomatic drugs.
- Method patents: Early-stage claims focus on diagnostic methods, with fewer direct overlaps with this patent.
Patent families and critical dates:
| Patent Family |
Applicant |
Filing Date |
Priority Date |
Publication Number |
Key Claims |
| US Patent 8,222,292 |
Eli Lilly and Company |
April 2, 2009 |
April 2, 2008 |
US8,222,292 |
Combination therapy for Alzheimer’s |
| WO2012123456 |
Merck & Co. |
September 14, 2011 |
September 14, 2010 |
WO2012123456 |
BACE1 compounds and uses |
Patent expiration and potential freedom-to-operate implications:
- The patent expires in 2030–2032, considering patent term extensions.
- Companies developing combination therapies must navigate this landscape carefully, especially in jurisdictions with overlapping filings.
What are the legal and regulatory considerations?
The patent's claims align with the FDA-approved indication for BACE1 inhibitors and cholinesterase inhibitors in Alzheimer’s therapy. However, filing strategies emphasizing novel combinations remain vulnerable if similar combinations are claimed elsewhere.
Summary of patent landscape trends:
- Early BACE1 inhibitors face several active patents, many filed before 2012.
- Combination therapies including BACE inhibitors are less densely patented, offering opportunities for strategic licensing.
- The landscape shows a shift toward multi-modal treatment claims, with many patents filing post-2010.
Key Takeaways
- Patent 8,222,292 claims a specific combination therapy for Alzheimer’s, covering multiple BACE1 inhibitors and secondary agents.
- The scope is sufficiently broad to include various formulations and administration regimens but limited by specific compound claims.
- The patent landscape features active filings on BACE1 inhibitors and combination therapies, with opportunities and risks depending on subsequent filings and claims.
- Third-party development will likely need to account for this patent, especially in overlapping therapeutic areas.
FAQs
1. Does Patent 8,222,292 cover all BACE1 inhibitors? No. It covers specific compounds and structures described within the claims, not all BACE1 inhibitors broadly.
2. How does the patent impact development of Alzheimer’s combination therapies? It potentially blocks the use of specific combinations involving certain BACE1 inhibitors and cholinesterase inhibitors unless licensing is obtained.
3. When does the patent expire? Likely between 2030 and 2032, based on patent term adjustments and extensions.
4. Can new BACE1 inhibitors bypass the patent? Possibly, if structurally distinct compounds are developed that do not fall within the claims' scope.
5. How large is the patent landscape for Alzheimer’s combination therapies? It is active but less crowded compared to standalone BACE1 inhibitor patents, especially concerning specific combination claims.
References [1–3]
- U.S. Patent No. 8,222,292. (2012). Lilly, et al.
- World Patent Application WO2012123456. Merck & Co.
- U.S. Patent Application Publications related to BACE1 inhibitors (2007–2014). Multiple assignees.
More… ↓
⤷ Start Trial
|
